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Summary
Purpose: There is a need for identifying molecular prognos-
tic biomarkers to better predict clinical outcomes in patients 
with renal cell carcinoma (RCC). This study investigated the 
pattern of cyclin D1 and p57 expression in RCC patients and 
evaluated their relation with clinicopathological character-
istics and overall survival (OS).
Methods: Immunohistochemistry was applied to paraffin-
embedded tissue sections of 74 RCC patients. Two cut-off 
groups were defined by the fraction of positive cells as fol-
lows: ≤10% and >10% positive cells for cyclin D1, and ≤5% 
and >5% positive cells for p57.
Results: Cyclin D1 expression in >10% of positive cells was 
observed mostly in the clear cell RCC, while p57 expression 
in ≤5% of positive cells was found in 86% of chromophobe 
RCC specimens. The higher expression of cyclin D1 and lower 
expression of p57 were more frequent in grade I-II tumors. 
OS was associated with unfavorable clinicopathological 
characteristics. However, cyclin D1/p57 expression did not 
influence the survival rates.
Conclusion: Although cyclin D1 and p57 expression did 
not affect survival rates in RCC patients, proper validation 
and establishment of the qualitative cut-off point are needed 
for these tumors.
Key words: cell cycle proteins, cyclin D1, immunohistochem-
istry, renal cell cancer, p57, survival
Introduction
 Renal cell carcinoma (RCC) is the most com-
mon adult malignant kidney tumor and it is also 
the most lethal urological tumor [1]. Disease rarely 
develops under the age of 40 (7%) and it usually 
affects male patients aged 60-70 years. During the 
last two decades, incidence rates increased ap-
proximately by 2% per year in both Europe and 
worldwide [2], however, in recent years stabilizing 
and declining trends were observed [3]. In Serbian 
population, the number of patients with RCC in last 
10 years has increased [4].
 Cell cycle is finely tuned by mechanism con-
sisting of protein complexes that include cyclins, 
cyclin-dependent kinases (CDK) and cyclin-de-
pendent kinase inhibitors (CDKI). Impairment of 
the cell cycle can lead to uncontrolled cell division 
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and neoplastic transformation [5,6]. Cyclin D1 is 
expressed through G1 phase into mitosis and in 
association with CDK4 and CDK6, it has a role in 
the regulation of the cell cycle through the retino-
blastoma (Rb) tumor suppressor protein [7,8]. In-
creased expression of cyclin D1 was found in many 
malignant tumors (breast, esophagus, liver, some 
types of lymphoma) [9]. Approximately 75% of RCC 
have higher expression of cyclin D1 than normal 
renal tissue [10]. 
 p57 is a member of the Cip/Kip family of CDKI 
molecules along with p21 and p27. Its role includes 
cell-cycle control, differentiation, apoptosis, tumo-
rigenesis and angiogenesis, migration and inva-
sion [11]. p57 has an active role in the development 
of lung, breast, bladder, prostate, gastrointestinal 
tract and pancreatic cancer [12]. This is the only 
CDKI that is necessary for normal progression of 
the cell cycle, as other inhibitors cannot compen-
sate its effect [11].
 Current clinicopathological prognostic factors 
such as stage, grade and performance status pro-
vide important prognostic information. However, 
they lack the potential to incorporate the individual 
biological potential and predict clinical behavior 
of tumors. Molecular markers have the capacity to 
interrogate biological heterogeneity of tumors and 
may ultimately help clinicians offer individualized 
treatment regimens. 
 Based on the above information, there is a need 
for a prognostic marker that might act as substi-
tute and research has been focused on identifica-
tion of specific and sensitive biomarkers [13]. The 
aim of this study was to determine the immuno-
histochemical expression of cyclin D1 and p57 in 
patients with RCC and to analyze them in relation 
to clinicopathological parameters and OS.
Methods
 This retrospective study included 74 patients with 
RCC who underwent nephrectomy between 2010-2013 
in the University Hospital “Dr. Dragisa Misovic” and the 
Clinic of Urology, Clinical Centre of Serbia, and were 
diagnosed at the Institute of Pathology, School of Medi-
cine in Belgrade. The study was performed in compli-
ance with the ethical standards of the Institutional Eth-
ics Committee and with the 1975 Helsinki Declaration. 
 Clinicopathological characteristics of patients in-
cluded age, gender, tumor size, nuclear grade (accord-
ing to the Fuhrman grading system) [14], TNM stage, 
histological subtype (according to 2004 WHO classifica-
tion) [15], and vital status. OS time was defined as the 
time from surgery to death or the last follow-up visit. 
Patients who were still alive at the final follow-up date 
were censored. 
Figure 1. Immunohistochemical staining of cyclin D1 and p57 in renal cell carcinoma. (A) cyclin D1 expression in 
≤10% of tumor cells; (B) cyclin D1 expression in>10% of tumor cells; (C) p57 expression in ≤5% of tumor cells; and
(D) p57 expression in >5% of tumor cells. Original magnification x 20.
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Figure 2. Kaplan-Meier curves for overall survival in patients with renal cell carcinoma. (A) Survival rate of the cohort. 
Survival rate according to (B) tumor size, (C) Fuhrman grade, (D) stage, (E) cyclin D1expression and (F) p57 expression.
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Immunohistochemistry
 For immunohistochemical detection, rabbit poly-
clonal antibodies to cyclin D1(diluted 1:50, Thermo 
Scientific, USA) and to p57 (diluted 1:600, Santa Cruz 
Biotechnology, USA) were used. The whole procedure 
has been described in detail elsewhere [16]. 
 Based on different literature cut-off data, we clas-
sified the expression into 2 groups defined by the frac-
tion of positive cells in the tumor section as follows: 
≤10% positive cells and >10% positive cells for cyclin 
D1 (overexpression), and ≤5% positive cells and >5% 
positive cells for p57. The groups were considered as 
tumors exhibiting low expression of the cyclin D1 and 
p57 protein, and tumors showing high protein expres-
sion, respectively (Figure 1).
Statistics 
 Statistical analyses were performed using SPSS 
23.0 for Windows (SPSS Inc., Chicago, IL, USA). In or-
der to test the association between categorical variables, 
the contingency tables (Chi-square and Fisher exact test) 
were used. The 5-year OS rate was calculated by Kaplan-
Meier method and groups were compared using Log-
rank test. Univariate and multivariate Cox proportional 
hazards regression model was used to analyze the inde-
pendent factors related to prognosis. P values <0.05 were 
considered significant.
Results 
 Clinicopathological characteristics of patients 
are given in Table 1. Patients’ age ranged between 
33 and 85 years (mean 59.29) with male predomi-
nance (64.9%). The median tumor size was 4.83 cm 
(IQR=3.5-6.73). The majority of tumor diameters 
(47.3%) ranged between 4.1 and 7 cm. The rates of 
low (nuclear grade I and II) and high-grade RCC 
(nuclear grade III and IV) were 55.4% and 44.6%, 
respectively. Stages pT1 and pT2 were classified as 
low-stage tumors (56.8%) and pT3 and pT4 as high-
stage tumors (43.2%). At the time of diagnosis, the 
clear cell RCC (ccRCC) was the most frequent his-
tological subtype (66.2%), followed by papillary 
(pRCC) (24.3%) and chromophobe (chRCC) (9.5%). 
 Tables 2 and 3 show the associations among 
clinicopathological variables, cyclin D1 and p57 
expressions. The analysis showed a statistically 
significant difference only between the histological 
subtypes and cyclin D1 expression (p=0.000, Chi-
square test). The cyclin D1 overexpression was pre-
dominantly found in patients with ccRCC (95.7%). 
There was no statistical significance between the 
p57 expression and any of the clinicopathological 
parameters.
Survival analysis 
 The 5-year OS for all patients was 69.3% (Fig-
ure 2A). Statistically significant correlation was 
found between survival and tumor size (Log-rank 
7.33, p=0.026), grade (Log-rank 11.12, p=0.001), and 
stage (Log-rank 29.03, P=0.000) (Figure 2, B-D).
 The 5-year OS rates for each size were as fol-
lows: 87.1% for patients with RCC size ≤4 cm; 68.4% 
and 45.7%, for patients with tumor size 4.1-7 cm 
and >7cm, respectively (Figure 2B). After 5 years, 
the survival rate among subjects with low-grade 
tumors was 87.5%. In the high-grade tumor group, 
the survival rates were 93.9, 60.3 and 48.5% after 
1, 3, and 5 years, respectively (Figure 2C). Patients 
with low (1-2) stage tumors had survival rate of 
94.1%, while 36.4% of patients with stages 3-4 
were alive after a 5-year follow-up period. There 
was no significant association between gender, his-
tological subtype and survival rate (Log-rank 0.68, 
p=0.408; Log-rank 0.58, p=0.748, respectively). The 
5-year OS rates were 73.6% and 61.2% for men and 
women, respectively, and 69.9, 64.8 and 85.7% for 
ccRCC, pRCC and chRCC, respectively.
 The OS analysis based on cyclin D1/p57 ex-
pression level (Figure 2 E-F) revealed no statistical-
ly significant difference between the survival rates 
Characteristics Occurrence
n (%)
Age, years
≤50 13 (17.6)
51-60 25 (33.8)
61-70 27 (36.5)
>70 9 (12.2)
Gender
male 48 (64.9)
female 26 (35.1)
Size (cm)
≤4 24 (32.4)
4.1-7 35 (47.3)
>7 15 (20.3)
Grade
I-II 41 (55.4)
III-IV 33 (44.6)
Stage
1-2 42 (56.8)
3-4 32 (43.2)
Histology
clear cell 49 (66.2)
papillary 18 (24.3)
chromophobe 7 (9.5)
Vital status
alive 53 (71.6)
dead 21 (28.4)
Table 1. Clinicopathological characteristics of patients 
with RCC (n=74)
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for these two parameters (Log-rank 0.41, p=0.520; 
Log-rank 0.68, p=0.408, respectively). Taking into 
consideration only the ccRCC histological subtype, 
no significant difference in OS according to cyclin 
D1 and p57 expression was observed (Log-rank 
1.96, p=0.161; Log-rank 0.01, p=0.916, respectively).
 Cox’s univariate regression analysis showed 
that larger tumor size, higher grade and tumor 
stage significantly affected survival. Multivariate 
Cox regression analysis identified higher grade 
(p=0.035) and stage (p=0.001) as the independent 
predictors of survival (Table 4).
Discussion 
 Despite the advances in clinical treatment, 
immunotherapy, targeted cancer therapies, and 
chemo- or radiotherapy, the prognosis of RCC pa-
tients is still very poor. Renal tumorigenesis is a 
complex multistep process which also involves ab-
errations in cell cycle control through cyclins and 
their regulators [7]. 
 Cyclin D1 overexpression was demonstrated in 
various malignancies including colorectal cancer 
[17] and breast cancer [18], correlating with early 
cancer onset, tumor progression, shorter survival 
and increased metastases [19]. In a variety of kid-
ney tumors, cyclin D1 expression demonstrated 
diffuse positivity in clear cell kidney sarcoma [20], 
as well as in RCC with Xp11.2 translocation [21]. 
In our cohort of patients, the expression of cyclin 
D1 in more than 10% of positive cells, used as a 
cut-off value, was observed mostly in the ccRCC 
histological type, while about 90% of pRCC and 
100% of chRCC subjects had cyclin D1 expression 
in less than 10% of tumor cells. These findings are 
in accordance with the observations of Hedberg et 
al. and Lima et al. [22,23] in which the evaluated 
cell cycle proteins varied between the different RCC 
types. Studies carried out by Sukov et al. [24] and 
Zhao et al. [25], demonstrated absence of cyclin D1 
expression in chRCC. Regarding the tumor features, 
the study of Hedberg et al. [22] showed that low 
cyclin D1 protein level in the ccRCC was associated 
with high nuclear grade and large tumor size; how-
ever, we found no association between the levels 
of cyclin D1 expression and tumor stage or grade 
in this study. It was reported that expression of 
cyclin D1 may be controlled through regulation 
of transcription, or proteasomal degradation [17], 
Characteristics ≤ 10% positive cells (n=27)
n (%)
>10% positive cells (n=47)
n (%)
p value
Age, years
≤50 4 (14.8) 9 (19.1)
51-60 8 (29.6) 17 (36.2) x2=1.816
61-70 10 (37.0) 17 (36.2) p=0.611
>70 5 (18.5) 4 (8.5)
Gender
male 16 (59.3) 32 (68.1) x2=0.586
female 11 (40.7) 15 (31.9) p=0.460
Size (cm)
≤4 6 (22.2) 18 (38.3) x2=3.210
4.1-7 13 (48.1) 22 (46.8) p=0.201
>7 8 (29.6) 7 (14.9)
Grade
I-II 12 (44.4) 29 (61.7) x2=2.067
III-IV 15 (55.6) 18 (38.3) p=0.224
Stage
1-2 15 (55.6) 27 (57.4) x2=0.025
3-4 12 (44.4) 20 (42.6) p=1.00
Histology
clear cell 4 (14.8 ) 45 (95.7) x2=50.477
papillary 16 (59.3) 2 (4.3) p=0.000
chromophobe 7 (25.9) 0 (0.0)
Vital status
alive 18 (66.7) 35 (75.4) x2=0.514
dead 9 (33.3) 12 (25.5)  p=0.593
Table 2. Correlation between cyclin D1 expression and clinicopathological characteristics
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Characteristics ≤ 5% positive cells (n=43)
n (%)
> 5% positive cells (n=31)
n (%)
p value
Age, years
≤50 8 (18.6) 5 (16.0)
51-60 15 (34.9) 10 (32.3) x2=2.630
61-70 17 (39.5) 10 (32.3) p=0.452
>70 3 (7.0) 6 (19.4)
Gender
Male 25 (58.1) 23 (74.2) x2=2.037
Female 18 (41.9) 8 (25.8) p=0.218
Size (cm)
≤4 17 (39.5) 7 (22.6) x2=2.613
4.1-7 19 (44.2) 16 (51.6) p=0.271
>7 7 (16.3) 8 (25.8)
Grade
I-II 26 (60.5) 15 (48.4) x2=1.064
III-IV 17 (39.5) 16 (51.6) p=0.349
Stage
1-2 24 (55.8) 18 (58.1) x2=0.037
3-4 19 (44.2) 13 (41.9) p=1.00
Histology
clear cell 26 (60.5) 23 (74.2) x2=2.771
papillary 11 (25.6) 7 (22.6) p=0.250
chromophobe 6 (14.0) 1 (3.2)
Vital status
alive 33 (76.7) 20 (64.5) x2=1.325
dead 10 (23.3) 11 (35.5) p=0.310
Table 3. Correlation between p57 expression and clinicopathological characteristics
Variables Coefficient b HR 95% CI p value
Univariate analysis
Size (cm)  0.042
≤4 1.0 -
4.1-7 0.869 2.385 0.656-8.667 0.187
>7 1.634 5.127 1.358-19.355 0.016
Grade
I-II 1.0 -
III-IV 1.544 4.681 1.714-12.787 0.003
Stage
1-2 1.0 -
3-4 2.917 18.491 4.278-79.934 0.000
Cyclin D1
≤10% 1.0 -
>10% -0.282 0.755 0.318-1.792 0.523
p57
≤5% 1.0 -
>5% 0.358 1.430 0.607-3.367 0.413
Multivariate analysis
Grade 1.096 2.993 1.083-8.270 0.035
Stage 2.738 15.457 3.177-75.2 0.001
Table 4. Factors affecting overall survival in patients with renal cell carcinoma
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and a study of pediatric rhabdoid tumors pointed 
out downmodulation of cyclin D1 as crucial in the 
treatment [26]. As ccRCC is the most common histo-
logical subtype, it can be useful to further analyze 
transcriptional regulation of cyclin D1 expression.
 In adult tissues, p57 is mainly expressed in 
skeletal muscles, heart, brain, lung, kidney, pan-
creas, testis and placenta. It is involved in the 
regulation of different cellular processes includ-
ing apoptosis, differentiation, development, and 
migration in tumorigenesis [27]. Several studies 
demonstrated that lower p57 expression in lung, 
oral, oesophageal, gastric, colorectal, hepatocel-
lular and pancreatic malignancies was associated 
with poor prognosis [27]; however, the role of p57 
has been studied to a small extent in cardiovascular 
and renal pathologies [28] and it was found that p57 
was among the genes which were commonly down-
regulated in RCC [29]. No correlation was found 
between the expression of p57 and tumor stage, 
nuclear grade, tumor size and gender in this study. 
We also did not find any evidence of an associa-
tion between p57 expression and RCC histological 
subtypes; however, the low expression (in less than 
5% of positive tumor cells) was mostly observed 
in the majority of chRCC and pRCC specimens. In 
cell lines, downregulation of p57 increases the ex-
pression of cyclin D1, enhancing the cellular pro-
liferation [30], initiation and progression [31] and 
also accelerates the growth and invasion, as it was 
shown in hepatocellular carcinoma cells [32,33]. 
The importance of p57 downregulation in human 
cancers and relevance in tumor-targeted therapy 
is a subject of investigation. Some clinical stud-
ies suggested that absence of p57 abrogates the 
pro-apoptotic function of anticancer therapy and 
results in poor prognosis due to development of 
drug resistance [28].
 The prognostic role of cyclin D1 and p57 has 
not been resolved yet. Low levels of cyclin D1 were 
associated with worse prognosis [22]. Migita et al. 
[34] found that low cyclin D1 expression had a ten-
dency to shortened survival, but it was not con-
firmed as an independent prognostic factor in pa-
tients with ccRCC. The study of Aaltomaa et al. [35] 
also found no correlation between the expression 
of cyclin D1 and survival; however, high expression 
of cyclin D in correlation with good prognosis was 
demonstrated in study by Lima et al. [23]. Reduced 
p57 expression correlated with decreased survival 
[27] similarly to the recent studies of breast cancer 
cases which showed that decreased expression of 
p57 was associated with worse prognosis [36]. 
 In this study, the overall survival was associ-
ated with standard unfavorable clinicopathological 
characteristics including disease stage 3-4, histo-
logical grade III-IV and tumor size over 7 cm, as 
shown previously [4,37], but not with the level of 
cyclin D1 and p57 expression according to the cut-
off values we used.
 The common issue with immunohistochem-
istry is the determination of the extent of tumor 
positivity for a given marker that is biologically 
and clinically relevant. Different results can be 
obtained due to lack of consensus regarding the 
method of evaluating the expression of cell cycle 
markers, especially when defining a cut-off value 
for a high/low proliferative index in tumor cells. 
Some studies set the mean value of expression 
as the boundary value for the entire cohort study. 
Other authors evaluated the expression semi-quan-
titatively, so the results were divided into quartiles, 
with a cut-off value that exceeded the expression of 
this protein in the normal tissue [38]. Thus, future 
research should focus on the definition of the op-
timal limit values for the evaluation of the immu-
nohistochemical expression of cell cycle markers.
 Usually, a cut-off score is set arbitrarily and 
it varies between different reports. As indicated in 
the newest reports [39,40] since there is a lack of 
proper validation and establishment of the quali-
tative cut-off point for these tumor types, no cell 
cycle or proliferative biomarkers are currently used 
in routine care to guide treatment decisions. In our 
study, two cores we used to determine the expres-
sion of the investigated parameters may also not 
have been sufficient enough to capture the biology 
of the whole specimen.
 The heterogeneity of this tumor suggests that 
numerous pathobiological phenomena play an im-
portant role in its development. For the clinical 
outcome and therapeutic approach, it is of utmost 
importance to observe and interpret these differ-
ences. Therefore, in addition to already established 
prognostic factors, such as stage and grade, the cur-
rent research focuses on the molecular biology of 
the RCC, as it can help to improve the therapy for 
these patients. Data of immunohistochemical ex-
pression of the cell cycle proteins could contribute 
to molecular profiling and more precise subclas-
sification of the RCC, which might be applied in 
additional therapeutic modalities.
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